World J Mens Health.  2012 Aug;30(2):114-122.

Time-Dependent Changes of Erectile Function in Diabetic Rats: Role of Systemic Endothelial Dysfunction

• Choi WS
• Park K
• Paick JS
• Kim SW

Abstract

PURPOSE
To understand the potential contribution of systemic endothelial dysfunction to diabetic erectile dysfunction, and the time course of erectile dysfunction in a streptozotocin (STZ)-induced diabetic rat model.
MATERIALS AND METHODS
Among 84, 12-week-old Sprague-Dawley rats, 48 rats received intraperitoneal STZ and were classified into six groups of diabetes by the period of observation (n=8). The remaining 36 rats were also grouped, similar to the diabetic groups, and served as normal controls. After 4, 6, 8, 10, 12, and 14 weeks of diabetes (serum glucose >250 mg%), all rats underwent cavernous nerve electrostimulation (3 V, 0.2 ms, 30 sec) with varying frequency (2.5~20 Hz). At the end of the study, 8 ml of blood was taken to measure the plasma markers of endothelial function and glycosylated hemoglobin.
RESULTS
Compared to the control, significant reduction of erectile response was not observed until eight weeks after diabetes induction. The diabetic rats had elevation of all plasma markers except for l-selectin. However, the correlation analysis revealed that no systemic marker of endothelial dysfunction was associated with change in erectile function. Only the level of hemoglobin A1c (HbA1c) showed a modest but significant correlation with the peak intracavernosal pressure, corrected by mean arterial pressure (rho=-0.183), and the area under the curve of the cavernosometry (rho=-0.207).
CONCLUSIONS
Significant reduction of erectile function was not observed until eight weeks after the induction of diabetes. Except for HbA1c, there was no systemic marker associated with endothelial activation and erectile function in the diabetic rats.

Keyword

Erectile dysfunction; Diabetes mellitus; Rats; Endothelium

MeSH Terms

Animals
Arterial Pressure
Caves
Diabetes Mellitus
Endothelium
Erectile Dysfunction
Glucose
Hemoglobins
L-Selectin
Male
Plasma
Rats
Rats, Sprague-Dawley
Streptozocin
Glucose
Hemoglobins
L-Selectin
Streptozocin

Figure

• 

  Fig. 1 The effect of diabetes on body weight and serum glucose concentrations. (A) The rats were weighed at regular intervals for 14 weeks. (B) Blood glucose was measured every 2 weeks. Significant elevation of blood glucose was noted within 2 weeks of streptozotocin injection. ▪: nondiabetic control animals, ▴: streptozotocin-induced diabetic rats. *Statistically significant difference from control group at each point in time (p<0.05).

• 

  Fig. 2 Serial comparison of plasma markers between control and diabetic rats. The levels were measured after the tested rats were euthanized and blood was collected. (A) Intracellular adhesion molecule (ICAM), (B) e-selectin, (C) l-selectin, (D) von Willebrand factor, (E) high sensitivity C-reactive protein (hsCRP), (F) endothelin-1 and (G) hemoglobin A1c (HbA1c). *Statistically significant difference from control group at each point in time (p<0.05).

Reference

1. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007. 120:151–157.

2. Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med. 1989. 320:1025–1030.

3. De Angelis L, Marfella MA, Siniscalchi M, Marino L, Nappo F, Giugliano F, et al. Erectile and endothelial dysfunction in Type II diabetes: a possible link. Diabetologia. 2001. 44:1155–1160.

4. Pegge NC, Twomey AM, Vaughton K, Gravenor MB, Ramsey MW, Price DE. The role of endothelial dysfunction in the pathophysiology of erectile dysfunction in diabetes and in determining response to treatment. Diabet Med. 2006. 23:873–878.

5. Ahn GJ, Yu JY, Choi SM, Kang KK, Ahn BO, Kwon JW, et al. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl. 2005. 28:260–266.

6. Browne DL, Meeking DR, Allard S, Munday LJ, Shaw KM, Cummings MH. Diabetic erectile dysfunction-an indicator of generalised endothelial function per se? Int J Clin Pract. 2006. 60:1323–1326.

7. Nangle MR, Cotter MA, Cameron NE. IkappaB kinase 2 inhibition corrects defective nitrergic erectile mechanisms in diabetic mouse corpus cavernosum. Urology. 2006. 68:214–218.

8. Usta MF, Kendirci M, Gur S, Foxwell NA, Bivalacqua TJ, Cellek S, et al. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment. J Sex Med. 2006. 3:242–250.

9. Chen Y, Yang R, Yao L, Sun Z, Wang R, Dai Y. Differential expression of neurotrophins in penises of streptozotocin-induced diabetic rats. J Androl. 2007. 28:306–312.

10. Christ GJ, Hsieh Y, Zhao W, Schenk G, Venkateswarlu K, Wang HZ, et al. Effects of streptozotocin-induced diabetes on bladder and erectile (dys)function in the same rat in vivo. BJU Int. 2006. 97:1076–1082.

11. Italiano G, Marin A, Pescatori ES, Calabrò A, Artibani W, Pagano F, et al. Effect of streptozotocin-induced diabetes on electrically evoked erection in the rat. Int J Impot Res. 1993. 5:27–35.

12. Ari G, Vardi Y, Finberg JP. Nitric oxide and penile erection in streptozotocin-diabetic rats. Clin Sci (Lond). 1999. 96:365–371.

13. Park K, Ryu KS, Li WJ, Kim SW, Paick JS. Chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction. Eur Urol. 2008. 53:1282–1288.

14. Musicki B, Champion HC, Becker RE, Liu T, Kramer MF, Burnett AL. Erection capability is potentiated by long-term sildenafil treatment: role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol Pharmacol. 2005. 68:226–232.

15. Melman A, Zotova E, Kim M, Arezzo J, Davies K, DiSanto M, et al. Longitudinal studies of time-dependent changes in both bladder and erectile function after streptozotocin-induced diabetes in Fischer 344 male rats. BJU Int. 2009. 104:1292–1300.

16. Seligman BG, Biolo A, Polanczyk CA, Gross JL, Clausell N. Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2000. 23:1395–1400.

17. Clausen P, Jacobsen P, Rossing K, Jensen JS, Parving HH, Feldt-Rasmussen B. Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with Type 1 diabetes mellitus with microalbuminuria and overt nephropathy. Diabet Med. 2000. 17:644–649.

18. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA. 2004. 291:1978–1986.

19. Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care. 2005. 28:690–693.

20. Thorand B, Löwel H, Schneider A, Kolb H, Meisinger C, Fröhlich M, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med. 2003. 163:93–99.

21. Kretowski A, Gillespie KM, Bingley PJ, Kinalska I. Soluble L-selectin levels in type I diabetes mellitus: a surrogate marker for disease activity? Immunology. 2000. 99:320–325.

22. Dursun H, Cinaz P, Bideci A, Guven A, Aybay C, Elbeg S. Serum levels of sL-selectin and tumour necrosis factor-alpha in children with type 1 diabetes mellitus. Acta Diabetol. 2007. 44:1–5.

23. Bivalacqua TJ, Champion HC, Usta MF, Cellek S, Chitaley K, Webb RC, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A. 2004. 101:9121–9126.

24. Cellek S, Rodrigo J, Lobos E, Fernández P, Serrano J, Moncada S. Selective nitrergic neurodegeneration in diabetes mellitus - a nitric oxide-dependent phenomenon. Br J Pharmacol. 1999. 128:1804–1812.

25. Seftel AD, Vaziri ND, Ni Z, Razmjouei K, Fogarty J, Hampel N, et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology. 1997. 50:1016–1026.

26. Musicki B, Kramer MF, Becker RE, Burnett AL. Inactivation of phosphorylated endothelial nitric oxide synthase (Ser-1177) by O-GlcNAc in diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A. 2005. 102:11870–11875.

27. Cartledge JJ, Eardley I, Morrison JF. Impairment of corpus cavernosal smooth muscle relaxation by glycosylated human haemoglobin. BJU Int. 2000. 85:735–741.

28. Rhoden EL, Ribeiro EP, Riedner CE, Teloken C, Souto CA. Glycosylated haemoglobin levels and the severity of erectile function in diabetic men. BJU Int. 2005. 95:615–617.

29. Głowińska-Olszewska B, Tołwińska J, Urban M. Relationship between endothelial dysfunction, carotid artery intima media thickness and circulating markers of vascular inflammation in obese hypertensive children and adolescents. J Pediatr Endocrinol Metab. 2007. 20:1125–1136.

30. Lupattelli G, Lombardini R, Schillaci G, Ciuffetti G, Marchesi S, Siepi D, et al. Flow-mediated vasoactivity and circulating adhesion molecules in hypertriglyceridemia: association with small, dense LDL cholesterol particles. Am Heart J. 2000. 140:521–526.

31. van Haelst PL, van Doormaal JJ, Asselbergs FW, van Roon AM, Veeger NJ, Henneman MM, et al. Correlates of endothelial function and their relationship with inflammation in patients with familial hypercholesterolaemia. Clin Sci (Lond). 2003. 104:627–632.